Potential to reduce the need for repeat surgeries

In approximately 30% of cancer surgeries, pathology confirms that the tumor was not extracted with clean margins. This means that cancer cells were left behind and the patient may need to undergo a second surgery. Lumicell aims to change this by helping surgeons see and and remove all cancer cells during the initial surgery, thereby decreasing the need for repeat surgeries, improving surgical outcomes, and reducing healthcare costs.


Lumicell is being developed to help illuminate cancer at the molecular level, enabling physicians to take action in real-time during surgeries to improve patient outcomes.


The company’s lead product, the Lumicell System, is in late-stage development for breast cancer surgery, and is also under investigation for ovarian, prostate, brain, colorectal, esophageal, and pancreatic cancers. It features an investigational onco-fluorescent agent and a handheld device that is being developed to help cancer surgeons to see and remove cancer cells in real-time during operations.


The Lumicell System was designed and developed by MIT engineers in partnership with leading breast cancer surgeons to fit seamlessly within the existing surgical workflow. The imaging agents and devices are optimized for the specific cancer-type and surgical procedure. The imager technology is based upon a novel imaging concept developed by W. David Lee while he was a member of the David H. Koch Institute for Integrative Cancer Research at MIT and a group of scientists, engineers, and clinicians from MIT and Duke University Medical Center. The proprietary molecular imaging agent was developed by Lumicell and is designed to fluoresce when in or near cancer cells at the tumor margin during surgical resection of the tumor. 




CAUTION – New Drug and Investigational device. Limited by Federal (or United States) law to investigational use.